This medicinal product has been authorised under a 'conditional approval' scheme. This means that further evidence on this medicinal product is awaited.

Resources for you and your patients

View and download these resources to help you start and manage your patients on ZYNLONTA

Downloadable resources

Pharmacy manual

Provides key information about ZYNLONTA for pharmacists and clinicians

Download pdf

Patient booklet

Provides information and support details for patients who have been initiated onto treatment with ZYNLONTA

Download pdf

Expert opinion videos

Listen to expert opinions on ZYNLONTA

Listen to Dr Adam Gibb, and Professor Graham Collins reflecting on their real world experience of ZYNLONTA and thoughts on changing treatment landscape in R/R DLBCL.

View videos

Real World Experience case studies

RWE case study insight

Dr Dungarwalla and Professor Collins discuss factors involved in considering when to continue or stop treatment and the importance of specialist nurses in this decision.

View Video

BSH 2024 highlights

Highlights collection

Watch short videos of views and thoughts from Dr Wendy Osborne and Professor Andy Davies at BSH 2024.

View videos

About ZYNLONTA

Contact

Need any further information?

Don’t hesitate to get in touch with any further questions you have

contact sobi

▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard (for United Kingdom) and www.hpra.ie (for Republic of Ireland). Adverse events should also be reported to Swedish Orphan Biovitrum Ltd at [email protected] or Telephone +44 (0) 800 111 4754.